Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Travel and Tropical Medicine
Under what circumstances do you recommend the chikungunya vaccine for travelers to areas without a current outbreak but with elevated risk, especially for extended stays?
Related Questions
How do you approach vaccination, particularly the use of live vaccines such as yellow fever, in a patient with rheumatoid arthritis receiving a TNF inhibitor who is planning travel to Africa?
Do you routinely recommend doxycycline for pregnant individuals with rickettsial diseases despite the historical concern for side effects in pregnancy?
Would you provide yellow fever vaccination or recommend insect precautions only in otherwise immunocompetent patients over 70 years of age who plan to travel to endemic regions given the increased risks of adverse events with vaccination with advancing age?
What is your re-immunization strategy after auto SCT for patients with myeloma on dara/len maintenance?
Do you always stop dexamethasone at discharge for patients admitted with COVID requiring respiratory support (as done in the RECOVERY trial), or are there situations in which you will prescribe it to complete a 10-day course?
How do you counsel a patient diagnosed with HTLV-2 after an abnormal blood donor screening?
How long would you hold antibiotics before performing a vertebral biopsy to optimize culture yield in a patient who has been on empiric antibiotics for a week for suspected vertebral osteomyelitis?
How do you make decisions about decolonization for a chronic asymptomatic MRSA carrier?
What is your approach to the management of asymptomatic bacteriuria in an elderly patient without clear urinary symptoms but with cognitive changes and falls?
Would you offer live vaccines (e.g., MMRV/measles) to patients on bispecific antibodies for multiple myeloma?
